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ABSTRACT 
 
Ellis-van Creveld (EVC) Syndrome is a recessively inherited genetic disorder 
characterized by dwarfism, craniofacial abnormalities, skeletal deformities and dysplasia, 
and an approximate 60% incidence of heart defects.  EVC syndrome is associated with 
mutations in two genes, EVC and EVC2 (limbin), located on chromosome 4p16, whose 
functions remain unknown. The purpose of this MQP was to obtain clues to the functions 
of EVC and EVC2 proteins through the study of their cellular localization. Synthetic 
peptides from parts of the EVC and EVC2 proteins were used to make antibodies for 
Western blot and immunocytochemistry analyses. Immunocytochemical localization of 
the EVC2 protein in normal and patient cultured fibroblasts suggests that the EVC2 
protein is normally found in the nucleus, but is absent in some EVC patients. In contrast, 
the EVC protein normally appears in a peri-nuclear location. This research should 
provide information that helps identify the function of these proteins. 
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BACKGROUND 
Introduction to Ellis-van Creveld Syndrome 
 
History 
 EVC syndrome was first described by Richard W.B. Ellis of Edinburgh and 
Simon van Creveld of Amsterdam. The pair first wrote of EVC in 1940, after meeting en 
route to a medical conference. While talking they came to realize that each had a patient 
with the characteristics of a syndrome that would later bear their names. At the time they 
called the disease chondroectodermal dysplasia.   Throughout the 1950s various case 
studies were published, but little else became known about the disease.  
  
Description 
 EVC is a form of chondrodysplastic dwarfism. It is an autosomal recessive 
disorder, characterized by short limbs, short ribs, polydactyly, and dysplastic teeth and 
nails. A large percentage of patients also present with congenital cardiac defects. The 
most common is a defect in the atrial septation that produces a common atrium. 
(Galdzicka et al, 2002; Laufer-Cahana, 2002).   
 
Prevelance 
 EVC appears to affect families worldwide, with patients in Europe, the Americas, 
and even the Middle East.  In the general population, the disorder occurs about once in 
every 60,000 live births, but it is particularly prevalent among the Amish population 
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occurring in as many as 5 of 1,000 live births in the Amish communities of Pennsylvania 
(Laufer-Cahana, 2002). 
  
Life Consequences  
 A diagnosis of EVC syndrome usually occurs in utero or immediately following 
birth.  Once the diagnosis is made, a heart exam is usually performed. Surgery can be 
performed for craniofacial abnormalities, polydactyly, or orthopedic abnormalities.   A 
child with Ellis-van Creveld syndrome may be prone to respiratory infections such as 
pneumonia, and may have more difficulty recovering from illnesses because of a small 
chest or hypoplastic lungs (Laufer-Cahana, 2002).  EVC does not cause adverse mental 
or developmental abnormalities.  Despite some severe cases, the average EVC child can 
grow to 43-61 inches. 
 
Etiology of Ellis-van Creveld Syndrome 
 
Genetics 
 Presently the etiology of Ellis-van Creveld syndrome is unknown.   Metrakos and 
Fraser (1954) first described a possible hereditary factor in chondroectodermal dysplasia.  
It was not until 42 years later, in 1996, that Ellis-van Creveld syndrome was mapped to 
chromosome 4p16 (Polymeropoulos, et al 1996).   It is believed that EVC follows a 
typical autosomal recessive inheritance. However, there is evidence that in some families 
the inheritance does not follow traditional Mendelian rules.  In these families, more than 
fifty percent of the children are affected.  
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Gene EVC-1 
 Gene EVC was the first gene determined to play a role in Ellis-van Creveld 
syndrome, hence its designation (McKusick, 2000). Translation of the coding sequence 
gives a 990 amino acid long protein also known as EVC or DWF-1.  It has a molecular 
weight of 111.8 kDa.  Motif searches found a leucine zipper, three putative nuclear 
localization signals and a possible transmembrane domain (McKusick, 2000).    
 
Gene EVC-2 
 EVC2 was the second gene found to play a role in Ellis-van Creveld syndrome. 
EVC2 encodes a 1228 amino acid long protein, spans 166.4kb, and is divergent to and 
shares a promoter with EVC (Galdzicka et al, 2002).  Figure 1 shows the chromosomal 
location of EVC-2 relative to EVC. 
 
 
Figure 1: Gene Map Showing The Location of EVC2 Relative to EVC 
on Chromosome 4.   Source: http://www.ncbi.nlm.nih.gov/ 
entrez/ query.fcgi?db=gene&cmd=Retrieve&dopt= 
Graphics&list_uids=132884) 
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The transcriptional start sites of EVC and EVC2 are only 1643 bp apart. Protein EVC2 is 
predicted to have one transmembrane segment, three coil coiled regions and one RhoGEF 
domain. (Galdzicka et al, 2002)  
 
Exclusion of the MSX1 Homeobox Gene 
 As with the EVC-1 and -2 genes, the MSX1 homeobox gene also maps to 
chromosome region 4p16.1.  The msx genes are known to be involved in pattern 
formation of the developing limb bud and craniofacial bones in the mouse embryo (Ide et 
al, 1996).  The gene family shares a 180-kb sequence of DNA encoding the highly 
conserved homeodomain. Members of the family have been found in various classes of 
organisms from Drosophila to chickens, frogs, and humans.  
 To determine whether MSX1 may be related to EVC syndrome, Ide et al 1996, 
created Msx1-defient mice which exhibited abnormalities in mandible and tooth 
development, as well as craniofacial development. There were, however, no 
abnormalities in the limbs or heart as one would expect in EVC. The authors suggested 
that despite the lack of limb abnormalities the “[msx1] expression pattern in embryos in 
the forming limb bud and neural crest implicate this gene in skeletal dysmorphologies…”    
Later sequence analysis of msx-1 in EVC patients, obligate carriers, and normal 
individuals, revealed no mutations in the coding region of the gene. Consequently, 
mutations in the msx homeobox domain were ruled out as a possible cause for Ellis-van 
Creveld syndrome.  
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Immunochemistry 
 The term immunochemistry was first used and coined by the scientist Arrhenius 
in 1907 (the Antibody Resource Page). This phrase summarized the combination of 
biology and chemistry in the study of antibodies. It is now used in the study of additional 
cellular products, but uses antibodies as the main method of identifying the target. 
 
Western Blots 
A western blot, also known as an immunoblot, is a combination of gel 
electrophoresis, protein transfer and an antibody assay used for detecting proteins in a 
supernatant or other solution. There are other similar types of blots that are used to 
identify RNA, DNA and other types of cellular products. A western blot uses antibodies 
with peptide sequences that have been created to bind with a specific peptide sequence in 
a protein. These peptide sequences are injected into animals to induce an immune 
response to the foreign protein, and the antibody is collected from the serum of the 
animal. These antibodies are known as the primary antibodies, as they make direct 
contact with the desired protein. In order to detect the bonded antibodies and protein, a 
secondary antibody is created and a type of label is attached. The secondary antibody is a 
product induced in a different animal than the first one, used to create the primary. The 
primary antibody is injected into the second animal, and the immune response creates an 
antigen which will then attach to the primary antibody.  
The secondary is used to detect the protein that the primary has already 
discovered and makes its presence known through the use of a label. One of several 
different types of label is attached; radioactive molecules, fluorescein, horseradish 
peroxidase, etc., to act as a detection tool when the membrane containing the protein is 
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placed next to X-ray film.  For this MQP, the label of choice was an enzyme conjugate 
that chemically converts the chemilluminescent substrate to emit light detected by the 
film. The combination of primary and secondary antibodies allows the visual ability to 
locate and identify the presence of specific proteins and their sizes.  
 
Immunocytochemistry 
 The technique immunocytochemistry is very similar to that of western blots. The 
use of primary and secondary antibodies, the methods of antibody induction, the 
procedure for carrying out the technique are all the same. However, this practice is 
carried out on whole cells or tissues. The purpose of immunocytochemistry is to enable a 
scientist the ability to locate the target they are studying in the cell.  
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PROJECT PURPOSE 
The purpose of this MQP was to obtain clues to the functions of EVC and EVC2 
proteins through the study of their cellular localization. Synthetic peptides from parts of 
the EVC and EVC2 proteins were used to make antibodies for Western blot and 
immunocytochemistry analyses. Once identified, the proteins were used in 
immunofluorescence localization experiments to help assign a cellular function for EVC 
and EVC2. 
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METHODOLOGY 
 
Western Blots for the different antibodies were performed using EVC patient 
samples X193, B136, 1352, 895, 891, 877, 874, 873, and 850. The original form of the 
samples was a cell pellet taken from patient blood samples, and a protein extraction step 
was required to make the desired EVC protein accessible in the supernatant. The EVC 
antibodies were created using chickens by Aves Labs, Inc® from peptide sequences that 
Dr. Ginns and Dr. Galdzicka had requested, and the Limbin EVC2 antibody was 
commercially available through AbCam®. 
 
Western Blots 
 
Preparation of Whole Cell Lysates 
Cell lines of patient samples collected from blood, were maintained and 
subsequent cell cultures were frozen and stored at -80˚C for future use. After thawing on 
ice, each of the sample pellets were resuspended in approximately 750 µL of Extraction 
Buffer, 60mM Potassium Phosphate with 0.1% Triton X-100 at pH 5.9. After the 
resuspension, the samples were flash frozen on dry ice to lyse the cells. Once the samples 
were frozen they were returned to ice to allow them to slowly thaw. Gentle rubbing was 
used to aid the thawing process. 
Once the samples had thawed they were brought to the UltraSonic Sonicator™ at 
50 Watts for 10 seconds three times. In between each sonication, the sample was kept on 
ice. The samples were then centrifuged at 14,000rpm for 5 minutes at 4˚C to pellet cell 
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debris. The supernatant, which contained soluble proteins, was removed and placed into 
clean 1.5 mL tubes that were labeled with the sample numbers, and stored at –20˚C.  
The remaining cell debris pellet was also processed for analysis by resuspension 
in an additional 750 µl or a five times approximate volume of the Extraction Buffer. The 
suspension was homogenized for 30 seconds and stored at -20˚C. 
 
BCA Protein Assay 
 The Pierce BCA Assay Kit™ was used to determine the protein concentrations 
present in the cell lysate and pellet samples. Using the 2.0 mg/ml BSA standard, 8 
standard curve dilutions were set up, as in Table 1.  
         Table 1.  BSA Assay Standard Concentrations. 
Volume BSA Volume dH2O  
Final BSA 
Concentration 
300 ul Stock 2.0 
mg/ml BSA 0 ul 2000 µg/ml 
375 ul Stock BSA 125 ul 1500 ug/ml (A) 
325 ul Stock BSA 325 ul 1000 ug/ml (B) 
175 ul of A 175 ul 750 ug/ml (C) 
325 ul of B 325 ul 500 ug/ml (D) 
325 ul of D 325 ul 250 ug/ml (E) 
325 ul of E 325 ul 125 ug/ml (F) 
100 ul of F 400 ul 25 ug/ml (G) 
 
To prepare Reagent Mix, Reagent A from the kit was diluted 1:50 with Reagent 
B. (24.5 mL of Reagent B + 500 µL of Reagent A). The tube containing the mix was 
vortexed to ensure the reagents were homogeneously distributed. EVC sample tubes 
contained 100 µL of a 1:10 dilution of the sample. 2 mL of the Reagent Mix was then 
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added to each tube and the sample was mixed using the micropipette and placed back in 
the rack. One test tube containing only 100 µL of water and the 2 mL of reagent was 
made and used as a “blank.” All of the test tubes were covered with parafilm and placed 
in a 37˚C water bath for 30 minutes. After the incubation, the test tubes were immediately 
placed on ice to stop the reaction. Each sample was read in the spectrophotometer relative 
to the blank.  Sample concentrations were determined by comparison to the BSA standard 
curve.   
 
Sample Preparation for Electrophoresis 
A volume of sample containing 15 µg of protein was mixed with dH20 to make 5 
µl, then 5 µL of loading buffer plus reducing agent was added. Sample tubes were placed 
into boiling water for two minutes then briefly microfuged. 
 
Gel Electrophoresis 
 For electrophoresis pre-made gels were purchased. To prepare the gels, they were 
removed from their protective packaging and the comb was removed to open the wells 
and the tape removed from the hard shell. Using a clean disposable pipette, 1x running 
buffer was used to clean the wells and remove any excess storage fluid and to eliminate 
any bubbles. Two gels were loaded into the gel box and then one half of the cover was 
forcefully inserted to create a seal between the gels and the probe. To test the seal, the 
external portion of the box was filled half way to ensure that no running buffer was 
leaking into the center between the two gels. Once that had been confirmed, the rest of 
the box could be filled with Electrode buffer, including the center to make sure that the 
wells were completely covered in buffer. 
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 Once the box was set up, the samples were loaded into a well plus two markers: 
XP BenchMark Antibody Ladder and the Pre-Stained Ladder. Elecrophoresis was at 40 
mA (one gel) or 80 mA (two gels) for about 90 min until the blue dye nearly reached the 
bottom of the gel.   
 
Protein Transfer 
 Once the gel has completed its run, the next step was to transfer the protein from 
the gel to a membrane for antibody staining. Approximately 2 L of transfer buffer was 
used for each run. In a graduated cylinder transfer buffer was made with 400 mL of 
Methanol, 28.82 g of Glycine, and 12.5 mL of Tris HCl pH 8.3. The Tris HCl was made 
using 6.25 mL of Tris HCl pH 9.0 and 6.25 mL of Tris HCl pH 7.4. The total volume was 
then brought up to 2 L of ultra pure filtered water. 
While the buffer was mixing 3MM filter paper and Immunoblot-P PVDF blot 
membranes were cut into the same size and shape of the electrophoresis gel. Two pieces 
of filter paper and membrane were needed for each gel. A western blot tray, which 
contained 100% methanol, was used to soak the membranes, while another tray 
containing the transfer buffer soaked the large and small sponges and filter paper. After 
the membrane had soaked for a few minutes in the methanol, it was moved to the tray 
containing the transfer buffer to rinse off. Once the gel was ready, a plastic cage was used 
to keep the sponges, gel and membrane together. The cage was laid flat; one or two 
sponges were placed on either side, followed by a thick white sponge on top of the 
sponges, then a piece filter paper, and then the membrane, followed by the gel. The cage 
was closed together and was tightly packed. The gel should be in the middle of the 
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“sandwich” with identical items flanking it on both sides. The membranes and gel must 
be kept wet at all times using the transfer buffer. 
The sandwich was then taken to the transfer chamber which was filled with the 
transfer buffer. The cover was placed on the chamber and the transfer program of 25 
mAmps for 20 minutes, 70 mAmps for 4 hours, and 100mAmps for 12-24 hours was set. 
This process was run overnight. 
Our results had large amounts of non-specific binding which lead to intense 
background, and in many cases it over-powered the banding signal. Through Aves it was 
discovered that chicken antibodies are infamous for their non-specific binding, and the 
effect is increased by using PVDF membranes. To try to counteract the non-specific 
binding the methodology was altered by using BlokHen II as a different blocking agent 
over the dry milk, and switched the PVDF membranes to nitrocellulose as recommended 
by Aves. To then determine the best combination of membranes and blocking agents, a 
“Dot Test” was performed using antibody 3693 to optimize the methodology.  
 
Membrane Incubations 
 Before removing the cages from the transfer box the washing buffer of 1x PBS 
plus 0.05% Tween 20 was made. Usually 500 mL of the solution was made at a time, 
with 250 µL of Tween 20 added to 500 mL of 1x PBS. The blocking solution of dry milk 
and PBS wash solution was made by adding 5 g of dry milk to 100 mL of wash. It was 
set on a plate and using a stir bar, was mixed for 15 minutes.  
The membrane that had taken up the Prestained Ladder was also the membrane 
that all of the protein from the gel had transferred to; the other membrane was empty and 
was discarded. Depending on whether the gel had been set up for one Western Blot or 
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two, if the gel had two identical sample sets then the membrane was cut down the XP 
Marker lane. Each membrane was placed into a dish labeled with the antibody that it 
would be washed with. To each dish containing a membrane, approximately 20 mL of the 
milk blocking solution was added. The dishes containing membrane and solution were 
placed on a shaker in an incubator at 37˚C for 1 hour. While the membranes were 
incubating the primary antibody solution was made. The solution was made with 1:500 
dilution of the primary antibody that was to be applied to the membrane. It was made 
with 20 mL of the blocking milk solution and 40 µL of the specified antibody. The 20 mL 
of the solution was added to the dish with the membrane that was set up to receive the 
antibody and was returned to the 37˚C incubator and shaken for 1 hour. 
After the hour the primary antibody solution was drained off the membranes and 
then approximately 15 mL of PBS Tween washing solution was added. The dishes were 
then placed on a shaker at room temperature for 5 minutes. After the 5 minutes, the 
washing solution was decanted and fresh washing solution was added and then the dishes 
were returned to the shaker for an additional 5 minutes. This was repeated one more time. 
During the final wash, the goat anti-chicken alkaline phostphatase secondary 
antibody solution was prepared following the directions from the WesternBreeze 
Chemilluminescent Kit. A 1:5000 dilution in 20mL of wash was used with the secondary 
antibody. Approximately 20 mL of the secondary antibody solution was added to the 
dishes and placed on the shaker in the 37˚C incubator for 30 minutes. The PBS Tween 
washes were then repeated three times only this time each wash was done for 10 minutes. 
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Immno-Dot Test 
 To optimize the banding signal and minimize the non-specific binding and 
background of the Westerns a dot test was performed for eight different sets of conditions 
(see Table 2), performed on both PVDF and nitrocellulose membranes.  
                                   
Table 2.  Conditions for the Immuno-Dot Test. 
Sample Blocker Primary Wash 
1 Milk 3693 PBS Tween 
2 Milk 3693 PBS 
3 BlokHen II 3693 PBS Tween 
4 BlokHen II 3693 PBS 
5 BlokHen II None PBS Tween 
6 BlokHen II None PBS 
7 Milk None PBS Tween 
8 Milk None PBS 
 
The PVDF membranes were treated as usual, but the nitrocellulose membranes followed 
a slightly different methodology. The PVDF membrane was activated in methanol, and 
the nitrocellulose was activated in purified water before being rinsed in transfer buffer. 
Both membranes were placed in a 50 mL conical tube and rotated at 37ºC in a rotator. 
The blocking step was preformed for an hour using 10 ml of the listed blocking solution. 
The washes were also performed in the incubator using 15 ml of the wash solutions. Each 
wash was performed three times at 10 minutes each. The primary incubation was also 
done in the incubator at 37°C for an hour. Blocker/Diluent A and B solutions from the 
WesternBreeze kit were used to make the solution, as instructed by the kit, to dissolve the 
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antibody. The primary antibody 3693 was diluted to 1:500, while the membranes that did 
not receive the primary antibody were incubated in the blocker/diluent solution alone. 
The incubation followed another series of washing as before. The secondary incubation 
was done in the incubator for 30 minutes. The goat anti-chicken alkaline-phosphatase 
secondary antibody was also dissolved into the blocker/diluent with a dilution of 1:5000. 
A final series of washes was performed on the membranes, prior to chemiluminescence. 
 
X-Ray Photographs 
 Once the washes were completed the chemilluminescent substrate, blotting paper, 
pipette with 5 mL pipette tips, and transparency paper were taken to the lab’s darkroom. 
The developing tank was filled with clean water and the developer and fixer solutions 
were made. Each bottle of Kodak GBX Fixer and Replenisher™ or Kodak GBX 
Developer and Replenisher™ was dissolved in water and brought up to 3.8 liters of total 
volume, or 1 gallon. Once the tank was ready, the membrane was taken out of the wash 
solution and placed on a plastic transparency sheet where 2.5 mL of the 
chemiluminescent substrate was applied and sat for 5 minutes. After the 5 minutes, the 
excess substrate was blotted off with blot paper and the membrane was covered with the 
other transparency. The lights were turned off and only the red safe light was on in the 
room. A piece of X-ray film was taken out of its protective cover and placed on top of the 
membrane and then covered by a black phosphor screen. Each X-ray film was exposed 
for differing amounts of time depending on how previous exposures appeared, but the 
average exposure was about five minutes. Once the exposure was done, the X-ray film 
was attached to a hanger and placed in the developer for 3 minutes. After the 3 minutes 
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the hanger and film were transferred to the water for 2 minutes to wash the developer off. 
The film was then moved to the fixer for another 3 minutes before being moved to the 
water to wash for a final 2 minutes. Once the film was in the water after the fixer, the 
lights could be turned back on to see the film image. The films were placed on another 
hanger where they could hang and dry. 
 
Immunocytochemistry 
Fibroblast cell lines from EVC patients were maintained in DMEM with 10% 
FBS in 6 well plates until they reached confluency. The media was siphoned off and the 
wells were washed with 1x PBS for 5 minutes. The PBS was then siphoned off and the 
10% buffered formalin was added and allowed to incubate at room temperature for 1 hour 
to fix the cells. After the hour, the formalin was removed and a PBS wash was performed 
three times at 5 minutes each. 
To block the cells, the PBS was removed and then approximately 750 µL of 0.1% 
BSA was added and incubated on a shaker at 37°C for 1 hour. The BSA was removed 
before adding 750 µL of the 1.0% BSA + PBS solution containing the Limbin primary 
antibody in a 1:1000 dilution. The primary was incubated at 37°C for 1 hour on a shaker. 
This primary antibody solution was removed and placed in a container where it was 
stored at 4°C and used for multiple incubations. The cells were then washed with 2-3 mL 
of PBS + 0.05% Tween 20 five times at five minutes each. Once the washes were 
complete the PBS wash was removed and the cells were incubated with 750 µL of the 
1:5000 diluted secondary antibody using rabbit anti-goat IgG (H+L) Alexa Fluor 488 
from Molecular Probes™ for one hour at 37°C. Once the secondary antibody had been 
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added, the plate was wrapped in aluminum foil to minimize light exposure, which can 
bleach the fluor. The secondary antibody solution was also removed and stored at 4°C for 
multiple incubations. The final five washes were performed with 2-3 mL of PBS + 0.05% 
Tween 20 for five minutes each prior to immunofluorescent detection performed on a 
PixCell II Microscope™. 
 
Immunocytochemistry Fixation Test 
An optimization of the immunocytochemistry procedure was performed to 
maximize the fluorescence of the limbin primary when attached in the cell and to 
minimize the background of secondary non-specific binding. The optimization was 
performed on a 12 well cell culture plate containing ML1 normal EVC patient fibroblast 
cells using six different sets of conditions (see Table 3). Each condition was performed 
twice, one with primary solution and the other without primary to act as a negative to test 
for non-specific binding. 
 
   Table 3 Fixation Optimization Conditions 
 
Condition Fixer Fixer Time 
(minutes) 
Detergent Detergent Time 
(minutes) 
1 Methanol 15 4mM Sodium 
Deoxycholate 
15 
2 Methanol 30 4mM Sodium 
Deoxycholate 
15 
3 Methanol 15 4mM Sodium 
Deoxycholate 
30 
4 Methanol 30 4mM Sodium 
Deoxycholate 
30 
5 Ethanol 15 4mM Sodium 
Deoxycholate 
15 
6 Ethanol 30 4mM Sodium 
Deoxycholate 
30 
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The optimization immunoassay was carried out similar to the immunocyto-
chemistry protocol. Wells were washed with PBS quickly to remove media before the 
fixation with the listed solution and time was performed. The wells were then washed 
three times at 5 minutes each using only PBS. Each condition was blocked for one hour 
using 1.0% BSA + PBS at 37°C on a shaker. The BSA was removed and 500 µL the 
1:1000 dilution of limbin primary antibody solution was applied for an overnight 
incubation at 4°C. The primary solution was then pooled and stored at 4°C for future use. 
Each well was washed five times for 5 minutes each using approximately 1.5 mL of PBS 
+ 0.05% Tween 20. The rabbit anti-goat secondary solution with a 1:1000 dilution was 
added to the wells and incubated for one hour at 37°C. The plate was wrapped in 
aluminum foil for the remainder of the experiment to minimize light exposure. The 
secondary solution was collected and saved at 4°C before being washed five times at 5 
minutes each using PBS + 0.05% Tween 20. 
The cells were kept in PBS after the final PBS + 0.05% Tween 20 wash to be 
viewed under the PixCell II™ microscope. Each well was viewed and compared to one 
another. An assessment on strength of signal was rated using a number system 1 thru 10 
with the strongest possible signal receiving a 10 and the lowest a 1. This information was 
used to select the most optimal fixation and permeability times. 
 
 
Immunoassay Secondary Antibody Dilution Test 
 
The next step was to determine the optimal dilution of secondary to have the 
maximum amount of signal, while attempting to minimize the amount of background. A 
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6 well plate containing ML1 normal EVC cell lines using the fixation method selected 
from the previous test, 15 minute fixation with Methanol followed by a 15 minute 
permeability, were tested for three different secondary solution dilutions (see Table 4). 
 
Table 4 Secondary Antibody Optimization of Dilutions 
 
Series Dilution of Secondary 
Antibody 
1 1:1000 
2 1:5,000 
3 1:10,000 
 
Each condition was performed twice, once with 1:1000 primary dilution and the 
other without primary antibody to act as a negative control. The same protocol for the 
immunoassays was repeated except for a few changes requested by Dr. Ginns. The plate 
was fixed with 3 mL methanol for 15 minutes, and then permeabilized with 4 mM 
Sodium Deoxycholate for 15 minutes. The plate was washed three times at 5 minutes 
each using PBS before 3 mL of the blocking solution of 1.0% BSA + PBS was added. At 
the request of Dr. Ginns, the blocking was performed for two hours over the usual one 
hour, at 37°C. The theory is that for the longer amount of time the cells are blocked, 
lower amounts of the secondary antibody will bind non-specifically to proteins in the cell. 
The primary dilution of 1:1000 was then added in amounts of 750 µL to each well and 
incubated overnight at 4°C. The primary was then collected and saved at 4°C for future 
use and washes were performed five times at 5 minutes each using PBS + 0.05% Tween 
20. The next change requested was that the series of secondary dilutions being tested 
were performed for an hour at room temperature. The plate was loaded with 750 µL of 
the listed dilution of secondary, covered with aluminum foil and incubated on a shaker at 
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room temperature for one hour. The secondary was removed and saved at 4°C for future 
use and the wells washed with 3 mL of PBS + 0.05% Tween 20 five times at 5 minutes 
each and then stored in fresh PBS at 4°C. 
The cells on the plate were observed using the PixCell II™ and rated on the 
strength of their signal. An assessment on strength of signal was rated using a number 
system 1 thru 10 with the strongest possible signal receiving a 10 and the lowest a 1. This 
information was used to select the most optimal dilution of the rabbit anti-goat secondary 
to minimize the amount of secondary needed to obtain the strongest signal and minimal 
amounts of background. 
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 RESULTS AND ANALYSIS 
 Prior to performing any bench research, a bioinformatic approach was used to 
identify potential glycosylation sites on the two EVC proteins to predict the extent of 
glycosylation and their expected sizes on immunoblots.   
 
Computer Analysis of EVC Protein Sequences 
 
 The NetOglyc program, from the Center for Biological Sequence Analysis (CBS), 
was used to carry out an analysis of the EVC sequence data, obtained from Dr. 
Galdzicka.  The NetOglyc server produces neural network predictions of mucin type 
GalNAc O-glycosylation sites in mammalian proteins.  Analysis gave possible O-
glycosylation sites at 478 and 545. Position 478 carried a 0.236 G-score, and an I-score of 
0.704, while position 545 had scores of 0.153 and 0.563, respectively, using the 
parameters previously established for analyzing mammalian O-glycosylation sites 
(Julenius et al, 2005).  
Another program, NetNGlyc, available from CBS, was used to determine whether 
there were potential N-glycosylation sites. The NetNglyc server predicts N-Glycosylation 
sites in human proteins using artificial neural networks that examine the sequence context 
of Asn-Xaa-Ser/Thr sequons. Analysis gave three possible N-glycosylation sites -109 
(0.7858 potential); 136 (0.6538 potential); and 831 (0.4996 potential).   Jury agreement 
for the three positions varied greatly.  Position 109 was declared a high probability (+++) 
N-glycosylation site with a 9/9 jury; 831 was ruled out with a 3/9 jury result, and 136 was 
declared a possible N-glycosylation site, but it prompted a “pro-x1” warning, meaning a 
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proline occurs just after the asparagine residue. Due to conformational restraints the 
asparagine is prevented from being glycosylated (Gupta, 2004).    
 Analysis of the EVC2 sequence with the NetNGlyc 1.0 server identified possible 
N-glycosylation sites at seven positions, all with jury values between 7/9 and 9/9.  
Positions 110 (potential 0.7583), 140 (0.6123), 208 (0.7287), 333 (0.7142), 485 (0.7482) 
each received jury result of 9/9, and are predicted N-glycosylation sites.  Positions 119 
and 193 were just as successful with jury results of 8/9 and 7/9, respectively (Gupta et al, 
2005).   Analysis of EVC2 with the NetOGlyc 3.1 server identified just one possible O-
glycosylation site at position 1069.  With a g-score of 0.240 and an I-score of 0.619 this 
position could be an O-glycosylation site, but it is unlikely (Julenius et al, 2005). 
 On the basis of the bioinformatic identification of potential glycosylation sites, we 
determined that because several such sites are present, the two EVC proteins likely exist 
as glycoproteins within the cell, so their sizes on immunoblots may be larger than 
predicted solely on the basis of their amino acid compositions. 
 
Antibody Sequencing 
Antibodies 3695 and 3693, induced against synthetic peptides EDH EER KLQ 
HLK TLQ and SRR RKR EVQ MSK DKE, respectively, were analysed using the 
Sequencher™ 4.2 program to determine where on the EVC protein the antibody 
recognition domain resided (see Figure 2).   
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Exon 1n
DWF-1 
Exon 2n
DWF-1 Sample 3693 Peptide
Exon 3n
Exon 15n
Exon 16n
DWF-1 Sample 3695 Peptide
Exon 17n
1 2,976384 2,098 2,5612,304
Figure 2: Locations of Antibody 3695 and 3693 Epitopes on EVC. 
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 The peptides that had been selected for injection were then analyzed using the 
Sequencher 4.2™ program to identify on which exon in the gene they resided. For 3695’s 
recognition sequence resides in exon 16 of the EVC1 gene. Due to the fact that one of the 
prominent EVC mutations being studied causes a stop codon on exon 13, the exon 16 
amino acid sequence would likely not be present in patient samples, so this ruled out the 
usage of antibody 3695 in future experiments (including the proposed 
immunohistochemistry experiment).   
Antibody 3693 recognizes an epitope located in exon 2 of EVC.  This antibody 
was used in subsequent immunoblot and immunofluorescence experiments, since exon 2 
should be present in most patient samples.  
Using the NCBI website (http://www.ncbi.nlm.nih.gov) it was determined that 
antibody 3660 recognizes an epitope present in the EVC2 gene starting at the 565th 
peptide of the 1228 peptide long protein. This places the antibody almost exactly in the 
center of the protein, before the known stop codon, so this antibody was also a viable 
option for subsequent experiments. 
 
Western Blot Analysis 
 Prior to the start of this project, chicken and rabbit antibodies were induced 
against specific regions of the EVC peptides.  Those antibodies, and a goat antibody 
(termed Limbin) directed against EVC2 (obtained from Abcam, Inc.) were assayed to see 
which had the highest affinity for EVC or EVC2 proteins.  Western blots using antibodies 
3693, 3695, 3626 and 3627 for EVC, and Limbin and 3660 for EVC2 were used in 
immunoblot experiments to test immunoreactivity using cell lystates prepared from EVC 
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patient samples (see Table 5). 
 
Table 5.  EVC Patient Samples. 
Sample 
Number 
Sample Type Identity Mutation Gene Procedure Utilized For 
B100 ASHKENAZI PATIENT homoz nonsense  EVC2 Western Blot 
B132 American PATIENT heteroz missense EVC2 Immunocytochemistry 
B136 American PATIENT homoz del_> 
frameshift->Stop 
EVC Western Blot; 
Immunocytochemistry 
B145 American PATIENT heteroz del-> 
frameshift->Stop/ 
heteroz missense 
EVC Immunocytochemistry 
B162 Taiwan PATIENT homoz nonsense EVC2 Immunocytochemistry 
EVC850 AMISH PATIENT homoz splice-> Stop EVC Western Blot 
EVC869 AMISH PARENT 
(OF 889) 
heteroz splice-> 
Stop  
EVC Western Blot 
EVC870 AMISH PARENT 
(OF 889) 
heteroz splice-> 
Stop  
EVC Western Blot 
EVC873 AMISH PARENT 
(OF 891) 
heteroz splice-> 
Stop  
EVC Western Blot 
EVC874 AMISH PARENT 
(OF 891) 
heteroz splice-> 
Stop  
EVC Western Blot 
EVC877 AMISH PARENT 
(OF 895) 
heteroz splice-> 
Stop  
EVC Western Blot 
EVC887 AMISH PATIENT homoz splice site 
mut -> Stop  
EVC Immunocytochemistry 
EVC889 AMISH PATIENT homoz splice-> Stop EVC Western Blot, 
Immunocytochemistry 
EVC891 AMISH PATIENT homoz splice-> Stop EVC Western Blot 
EVC895 AMISH PATIENT homoz splice-> Stop EVC Western Blot 
NSB1012 NORMAL NORMAL normal none Western Blot 
NSB1048 NORMAL NORMAL normal none Western Blot 
NSB1342 NORMAL NORMAL normal none Western Blot 
NSB1353 NORMAL NORMAL normal none Western Blot 
X193 Canadian 
(French) 
PATIENT heteroz del-> 
frameshift->Stop/ 
heteroz splice site 
mut 
EVC Western Blot 
Immunocytochemistry 
T0313 American PATIENT heteroz missense EVC Immunocytochemistry 
RD Netherland PATIENT unknown   Immunocytochemistry 
ML1 NORMAL NORMAL normal none Immunocytochemistry 
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In the beginning, both soluble proteins and debris pellets were analyzed from 
lysates prepared from stored patient tissue pellets to determine whether the EVC protein 
resided in the soluble fraction or debris pellet (see Figure 3). The lysate samples, seen in 
lanes 1 through 4, were remarkably different from the pellet samples seen in lanes 7-10 
(lanes 5 and 6 were a prestained ladder and XP ladder, respectively).   Using limbin 
antibody, bands were seen in the lystate lanes around 100 kDa in all patients tested on 
this blot (889, 1012, 1048, and 1353).   
 
Figure 3: Analysis of  Soluble Lysate Versus Pellet Samples for the 
Commercially Available Limbin Antibody.   Lane 1, extract 889; Lane 2, 1012; 
Lane 3, 1048; Lane 4, 1353; Lane 5, XP Marker.  
    
 
Eventually, the analyses concluded that only the soluble portion of the lysate 
samples should be used based on the observation that bands were found around 220 kDa 
in lysates of patient sample 889, but not in the pellet samples associated with this patient.   
Unfortunately, our results had large amounts of non-specific binding which lead 
to intense background, and in many cases it overpowered the band signals. It was learned 
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through Aves Labs, Inc. (Tigard, Oregon) that chicken antibodies are infamous for their 
non-specific binding, and the non-specific effect is increased by using nylon-based 
membranes. To try to counteract the non-specific binding, the methodology was altered 
by using BlokHen II as a different blocking agent over the dry milk, and by switching 
from the PVDF membranes to nitrocellulose as recommended by Aves.   
To determine the best combination of membranes and blocking agents, a “Dot 
Test” was performed using antibody 3693 (discussed below) to optimize the 
methodology. 
 
Antibody Limbin (Against EVC-2) Immunoblot 
 
Patient lysates were analyzed using the commercially available Limbin antibody 
against EVC-2 (Figure 4).  The 5 minute exposure (data not shown) showed the ladder as 
a smear so an attempt was made to try to resolve the ladder.  
 
Figure 4:  Analysis of Patient Samples Using Limbin Antibody 
Against EVC-2.   Lanes 1,2 Patient Sample 891; Lanes 3,4 Normal 
Sample 1012.   30 second exposure.   
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The 30 second exposure (Figure 4) showed several bands.  Nothing was observed 
at the 220 kDa mark in any sample (220 kDa was deemed worthy of consideration due to 
the fact that it was a non-expected band which may indicate different mutations not yet 
known in the EVC2 gene).  However, a band around 35 kDa was present in normal 
samples but not present in the patient samples, as expected if the patient samples had a 
mutated EVC protein. Also, there appears to be double bands around 80 kDa in all 
samples (marked in the figure with circles). 
 On the basis of these findings, antibody Limbin against EVC2 was chosen for 
further analysis (see below) because two different anomalies of interest between patient 
and normal samples were found.   
 
Antibody 3660 Against EVC2 
 Portions of this blot were not useable because of a bubble. This bubble was the 
result of a bad transfer.  Portions unaffected by this bubble were still valuable.  
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Figure 5: Test of Antibody 3660 Against EVC-2.  Lanes 1, 2 Patient 
Sample 891; Lanes 3, 4 Normal Sample 1012.  Five minute 
exposure. 
   
 
Bands were observed around 35 kDa and 80 kDa in patient 891 but not in normal (1012) 
samples, which is because the location of 3660 is different from the location of Limbin. 
3660 is located in the center of the EVC2 gene while limbin is located at the very end. 
This would result in different banding between the different blots.    
 
Antibodies 3626, 3627 (EVC2) 
These antibodies recognize the same EVC2 epitope as 3660 but come from 
different hens. The experiment shown in Figures 6 and 7, failed to yield any results 
because the gel lost its consistency, although the pre-stained ladder transferred correctly.  
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Figure 6: 3626 One minute exposure                      Figure 7: 3627 One minute exposure 
 
 
Antibody 3693Against EVC, Exon 2 
 Bands were observed around 100-85 kDa and 35 kDa in patients, but not in 
normal samples.  
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Figure 8: 3693   Figure 9: 3693  
Lanes 1, 2 Patient Sample 891; Lanes 3, 4 Normal Sample 1012 for both 
 
 A second blot confirmed the presence of the 100-85 kDa and 35 kDa bands in 
patient samples and but in the controls. There was also a very strong band in all samples 
around 55 kDa.   
  Another attempt was made but this experiment failed due to an unexplained error. 
The ladder became disorganized and had extra bands (data not shown). 
 
Antibody 3694 Against EVC1 
 A 30 second exposure was underdeveloped, however the 1 minute exposure 
produced bands (Figure 10).  
55 kDa 
35 kDa 
75 kDa 
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Figure 10: 3694 Overnight exposure                               Figure 11: 3694 One minute exposure 
Lanes 1, 2 Patient Sample 891; Lanes 2, 3 Normal Sample 1012 
   
The five minute exposure showed strong signals at 75 kDa in all samples. The overnight 
exposure showed what might be weak bands in the patient samples at 35 kDa.  
 
Antibody 3695 (EVC-1, exon 16) 
 This antibody was not used for analysis because its recognition epitope resides on 
exon 16, which comes after the stop mutation within exon 13 in a frequent EVC 
mutation.  At no point was the affinity for 3695 established by sequencing.  Despite 
attempts at optimization the antibody continued to demonstrate large amounts of non-
specific binding (data not shown). 
  
 
 
75 kDa 
35 kDa
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Optimization of 3693  
  
One of the problems encountered while testing the chicken antibodies was a high 
background. Contact with Aves indicated that PVDF and other nylon based membranes 
cause higher than normal non-specific binding, due to the interaction of nylon and 
chicken IgGs (Aves Labs, Inc., 2005).  Thus nitrocellulose was tested for antibody 3693. 
The nitrocellulose membrane was incubated with 3693 as the primary antibody for two 
different lengths of time (one hour and overnight). A 10-minute exposure of the first blot 
yielded faint bands below the 20 kDa marker (data not shown).  An overnight exposure, 
of the one hour incubation (Figure 12) yielded slightly darker bands at approximately 33 
kDa in patient (B100, 895) pellet samples. Also notable is banding seen below the 20 
kDa mark in B100 and 895 pellets. The results of the overnight incubation were not as 
expected.  The only observable signals after a thirty-minute exposure were a very faint 
XP ladder, a possible band in the 895 pellet around 45-50 kDA, and a smear in the B100 
patient lystate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12:  Test of EVC Antibody 3693 with 
Nitrocellulose Membrane.  Overnight Primary.  
30  minute exposure. 
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Dot Test 
 After the failure of the optimization procedure several other western blots were 
performed on nitrocellulose membranes using a procedure from Aves. These blots used 
antibodies 3693 and 3695 but most of these blots appeared not to have any bands on 
them.  In an effort to determine the best way to blot, a dot test was performed.  
 Sixteen different dot tests (refer to Methodology page 18 for more information) 
were performed to optimize the Western Blot protocol (Figure 13). Some of the factors 
tested were nitrocellulose versus PVDF, washing in PBS Tween versus PBS, use of 
primary antibody versus no primary antibody, and blocking with a milk solution versus 
BlokHen II. 
 
Figure 13: Nitrocellulose Dot Test. 
For “Dot Conditions” See Table 2  
 
The results for the nitrocellulose membranes (shown in figure 13) were quite 
interesting.  The 5-minute exposure showed a limited response from the nitrocellulose 
membranes, regardless of the conditions, however blot N8, carried out with milk block 
and washed with PBS Tween, had a very faint signal.  When using a longer overnight 
exposure, only the samples that were blocked using milk (N1, N2, N7, and N8) had a 
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visible signal. All of the membranes that had been blocked with BlokHen II had no 
signal.  N1 and its slightly stronger companion N2 had no background and detectable 
signal.  N7 and its companion with slightly stronger signal N8 were blocked using milk 
and did not receive 3693 during the primary incubation yet their signals were equal to 
those receiving primary antibody. This raised concerns about the validity of the signal 
obtained using a nitrocellulose membrane. This also raised concerns about the validity of 
any signal obtained using the goat anti-chicken alkaline-phosphatase secondary because 
obtaining a signal meant that the secondary was binding any number of unrelated 
proteins. The lack of response on the nitrocellulose membrane tests raised the possibility 
that our EVC proteins were not binding to the nitrocellulose for some reason.  
The PVDF dot test results (Figure 14) were more promising.  The 5-minute 
exposure showed several signals. The conditions for the PVDF dot test were the same as 
those for nitrocellulose but were performed on PVDF membranes instead. (See Table 2 
for exact conditions.)  P1 had a strong signal with a mostly clean background. P2 had a 
strong signal, but had the strongest non-specific binding and darkest background. P3 
which used BlokHen II, 3693 as the primary incubation and was washed using PBS 
Tween, had a clear signal, and one of the cleanest backgrounds. P4 had a very weak 
signal mainly because the background was nearly as strong as the signal itself. Blots P5 
and P6 had barely visible signals and were both carried out with no primary antibody 
added to the Blocker/Diluent solution. P7 had a clear signal with minimal background. P8 
had a clear signal, with the second most background. Overall it was determined that the 
blots blocked in milk had too strong of a background, while those blocked with BlokHen 
II had an acceptable balance of signal and background. Based on the information 
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obtained from the exposures the P3 procedure was determined to be the optimal 
procedure.  
 
 
Figure 14: PVDF Dot Test.  Five-minute Exposure 
For “Dot Conditions” See Table 2. 
 
Immunocytochemistry 
 Several immunocytochemistry experiments were performed on human fibroblast 
tissue culture samples of both normal and EVC patients. The EVC2 (limbin), chicken and 
rabbit antibodies were used to localize the EVC proteins in the cells.  
 
Immunoassay Fixation Test 
 Initially, the variation in fluorescence between positive and negative EVC2 
(limbin) tests in fibroblast tissue culture was minimal, so optimizations to enhance the 
differences were carried out.  An optimization was performed to create an ideal fixation 
process, which combined the fixing of the cells to the plate and making the cells 
permeable to uptake the limbin primary antibody and fluorescent rabbit anti-chicken 
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secondary. The entire procedure for this process and the conditions tested can be found in 
the Methods section, on page 21.  
 The system to compare the variations between the different tests was a rating 
method assigning values on a scale of 1 to 10. Values were assigned based on the 
brightness of signal in the cells in the different conditions compared to one another. The 
strongest signals received larger numbers than the cells with weaker signals. The 
condition with the largest positive difference between the limbin positive and negative 
samples was chosen as the fixation process to proceed with (see Table 6). 
 
Table 6:  Results of Fixation Optimization 
 
CONDITION Limbin (1:1000 dilution) NEGATIVE DIFFERENCE 
1 7 1 +6 
2 1 2 -1 
3 3 3 0 
4 6 3 +3 
5 8 3 +5 
6 3 4 -1 
 
 Condition 1 had the largest difference between the positive and negative test, a 
difference of +6, and was selected as the fixation process to continue experimentation. 
This condition utilized a 15 minute fixation step with Methanol and 15 minute 4 mM 
Sodium Deoxycholate permeability step.  
Another aide in the selection process for the optimal protocol included the 
appearance of the cells under the microscope. Cells that had been exposed to Methanol 
for 30 minutes and 4 mM Sodium Deoxycholate for 15 minutes had a shriveled 
appearance. Cells that were exposed to both solutions for 30 minutes had a bright fluor, 
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but the cells appeared to dissolve and were no longer intact, which would not aide in 
identification of a location in the cell. Ethanol had a similar shriveling and dissolving 
effect to the cells as Methanol, except that the cells were destroyed within 15 minutes. 
With the optimal times for the fixation process decided upon, the next step was to 
determine the optimal dilution for the secondary antibody. 
 
Secondary Dilution Series Test 
 The purpose of the dilution test (data not shown) for the secondary antibody was 
to determine the least amount of secondary antibody needed to give a fluorescence signal 
while minimizing the background. Because each well had a fluor, with a noticeable 
difference between the negative and the Limbin positive, it was concluded that the largest 
dilution, 1:10,000 was acceptable and was to be used in the immunocytochemistry 
methodology. 
 
Immunocytochemistry of Patient Samples with EVC2 (limbin) Antibody 
ML1 were the normal samples used as a comparison to the patient samples. When 
the EVC2 antibody (limbin) was used as the primary, and the ML1s were observed under 
a PixCell II Microscope, a signal was prominent (Figure 15).  Most notable was the 
presence of bright dots located in the nucleus. This is indicates that the normal and 
healthy EVC2 protein resides in the nucleus. 
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Figure 15: ML1 Limbin Antibody Primary (1:1000) 
 
There are many different forms and severity of the disease, and numerous 
mutations have been identified. Patient sample 887 has a distinct morphological 
difference than the normal ML1 fibroblast structure and the dots in the nucleus remain 
present (see Figure 16).  
 
Figure 16: Immunomicroscopy of Patient 887 With Limbin Primary. 
 
The patients B136, B132, B142, and B145, were all children when they died from 
the disease. According to Dr. Ginns, who maintained the cell lines, these cells were the 
most difficult to grow and were the last to adhere to the wells. They also have the most 
severe morphological changes from the healthy cells. The dots in the nucleus are absent 
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in B142 and it is clear that the cells lack the normal ML1 fibroblast appearance (see 
Figure 17). 
 
Figure 17: Immunomicroscopy of Patient B142 With Limbin Antibody. 
 
Immunocytochemistry of Patient Samples with EVC Chicken Antibodies 
ML1 were the normal samples used as a comparison to the patient samples. When 
the EVC antibody 3693 was used as the primary, and the cells observed under a PixCell 
II Microscope, a signal was prominent (Figure 18).  Most notable was the presence of a 
halo around the nucleus. This is indicates that the normal and healthy EVC protein 
resides in a peri-nuclear location. This may also indicate an association between the 
EVC2 protein (located within the nucleus) and the EVC protein (located peri-nuclear).  
 
 
 Figure 18: Immunomicroscopy of ML1 With 3693 Primary 
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This peri-nuclear localization was also seen when the EVC antibodies 3694 and 
3695 were used as the primary, and the cells observed under a PixCell II Microscope 
(Figures 19 and 20). 
 
                                
Figure 19: Immunomicroscopy of           Figure 20: Immunomicroscopy of ML1 
                     ML1 With 3694 Antibody.                                              With 3695 Antibody. 
        
 
Immunocytochemistry of Patient Samples with Rabbit Antibodies 
ML1 human fibroblasts were the normal samples used as a comparison to the 
patient samples. Rabbit antibodies that had been previously prepared by Dr. Galdzicka 
were tested against EVC patient cell lines. When the 809 antibody was used as the 
primary, and the cells observed under a PixCell II™ Microscope, a prominent signal was 
detected (Figure 21).  The cells tested for the EVC protein with antibody 809 were clearer 
than the other rabbit antibodies, the least grainy, and showed a striking presence of a halo 
around the nucleus.  
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Figure 21:Immunomicroscopy of ML1 With 809 Primary Antibody 
 
808K had the second best signal. It demonstrated a peri-nuclear localization, but 
there was not significant difference between this signal and background signal. Antibody 
802 had the worst affinity, and no picture was readily found to exhibit this.  
 
Figure 22: Immunomicroscopy of ML1 With 808K Primary. 
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DISCUSSION 
    
Dot tests, fixation experiments and other assays assisted in the determination of 
optimum conditions. The nitrocellulose versus PVDF dot test confirmed that PVDF 
membranes, blocked in BlokHen II, and washed in PBS-tween was the optimum 
immunoblot procedure (see Figure 14).  A 15-minute soak in methanol followed by 15-
minute soak in 4 mM Sodium Deoxycholate was determined to be the best possible 
fixation procedure based on the results of the fixation optimization (see Table 6). 
Throughout the various experiments performed, the commercially available Limbin 
antibody exhibited positive affinity for EVC2 proteins. This affinity varied between 
normals and some patients, such as normal 1012 having an additional 35 kDa band which 
was clearly absent in patient 891 (See Figure 4). This discrepancy indicates the 35 kDa 
band may play an important part in the expression of the disease in patient 891 and 
potentially other patients.  In culture, the limbin antibody produced a punctuate pattern in 
the nucleus of normal and some patients (see Figures 15 and 16).   
A total of eighteen different patient, and five normal samples were tested between the 
immunoblot and immunocytochemistry experiments. Samples 887, B145, B162, RD, and 
TO313 were used for immunocytochemistry experiments only. The remaining samples 
were used in immunoblots. Patient samples 889, B136 and X193 were used in both 
immunoblot and immunocytochemistry experiments (see Table 5). Sample 889 
demonstrated double banding around 80 kDa, and banding around 35 kDa in 
immunoblots incubated with limbin. B136, and X193 did not stand out against other 
samples in immunoblots. The X193 cell line did not grow well in culture and 
immunocytochemistry results were not conclusive. Both samples 889 and B136 
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demonstrated fluor in the nucleus under EVC2 staining.  
Patient samples B145 and B136, which were negative for EVC2 protein, were the 
only patients from the study that possessed frameshift mutations in the EVC gene. A third 
patient line, X193, contained the mutation but did not grow adequately in culture. This 
frameshift potentially results in downstream errors in EVC2 translation. During the 
course of the experiment it was noted that B145 samples had a minority of cells in each 
well demonstrating a positive fluor for the EVC2 protein. B145 contains an additional 
mutation, a missense in EVC, which is unlikely to affect the EVC2 gene. This produces a 
potential explanation for the lack of fluor uniformity of B145 cells, despite the large 
portion of cells, which tested negative. 
These results also demonstrate a relationship between EVC and EVC2 genes. This 
supports previous research, performed by Galdzicka et al, which suggested that the EVC 
and EVC2 genes are arranged in a “head to head” configuration and may influence one 
another during transcription.  The failure of EVC to properly function may inhibit the 
transcription or packaging of EVC2 as evidenced by the lack of fluor in samples B145 
and B136, which contained the frameshift mutations.  
EVC banding was expected at 112 kDa, while EVC2 banding was expected at 140 
kDa.  At this point in time there is uncertainty whether any of the bands observed in our 
immunoblots had the expected sizes for either of the glycosylated proteins. Double bands 
were consistently present around 80 kDa in both patient and normal samples when tested 
with the EVC2 antibody.  This was unexpected.  
Regarding the immunofluorescence experiments, Kamei et al (1995) have identified 
dot-like structures in the nucleus as well, these structures were known to contain mostly 
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coilin, an 80 kDa protein.  While the research performed by Kamei et al was not done to 
gain information on Ellis-van Creveld Syndrome, or used any of the same antibodies, the 
similarities to its presence and structure in the nucleus is why the information could point 
to a direction in the function of the “dots” in EVC and should be pursued. These coiled 
bodies are thought to be involved in RNA processing (Kamei, 1995).   Further research 
into these findings may reveal a co-localization of colin and EVC2 protein with these 
nuclear structures.  
 The optimization of cell line X193 (see Table 5) would allow tests to be 
conducted in an effort to identify any similarity to B145 and B136.  If similarities exist 
then it can be suggested that an EVC mutation causes a later mistake in EVC2 translation 
or transcription, thus demonstrating a relationship between EVC and EVC2. Similarly, 
An organ blot should be performed to determine whether EVC proteins are tissue-
specific. The analysis could be extended to include tissues at various stages of 
development to help determine EVC’s role those processes.  
 Rabbit antibodies against EVC peptides were induced in an attempt to avoid the 
high background associated with chicken antibodies. Preliminary investigations with 
rabbit antibodies showed a promising beginning in cell culture experiments for affinity to 
EVC. These results have been consistent with those obtained with the anti-EVC chicken 
antibodies. Both demonstrate EVC protein localized in a peri-nuclear fashion. Further 
research should be conducted into these antibodies. However, confirmation should be 
made through Western blots or other assays to determine if these are in fact identifying 
EVC.  
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 The results of these findings and future recommendations could help in the 
identification of the functions of these otherwise unknown proteins and potentially 
uncover a treatment or cure for this debilitating and rather obscure disease. 
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